Actively Recruiting
Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer
Led by Shu Wang · Updated on 2024-12-02
285
Participants Needed
1
Research Sites
886 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Human epidermal growth factor receptor 2 (HER2) positive breast cancer is a molecular subtype with high malignancy and high risk of recurrence and metastasis. HER2 targeted drugs has greatly improved the prognosis and survival of such patients. At present, for HER2 positive breast cancer patients with negative lymph nodes, chemotherapy drugs combined with trastuzumab is the current standard treatment scheme, and in most cases, chemotherapy uses a combination of two drugs, while the main beneficiaries of the trastuzumab and paltuzumab are concentrated in the group of patients with positive lymph nodes. Can targeted therapy be used to reduce the progression of chemotherapy and further achieve efficient and low toxicity strategies. To explore the efficacy and safety of adjuvant therapy of taxane chemotherapy combined with trastuzumab targeting therapy for low-risk HER2 positive and lymph node negative early breast cancer.
CONDITIONS
Official Title
Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Treatment at Peking University People's Hospital for radical breast cancer surgery with hospitalization records
- Postoperative invasive breast cancer confirmed by pathology
- Tumor stage T1a-b (tumor size ≤1 cm), N0, HER2 positive with high-risk factors (grade 3 or hormone receptor negative)
- Tumor stage T1c (tumor size between 1 and 2 cm), N0, HER2 positive without high-risk factors (grade 1 or 2, hormone receptor positive)
- Signed agreement to participate in the PKUPH Breast Disease Cohort study at Peking University People's Hospital
You will not qualify if you...
- Missing clinical pathological data such as imaging or pathology reports
- Received preoperative neoadjuvant therapy
- Having metastatic or bilateral breast cancer
- Did not undergo curative surgery
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University People's Hospital
Beijing, Beijing Municipality, China, 100044
Actively Recruiting
Research Team
Y
yuan peng, doctor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here